This section covers the biology of ageing at the level of the specific pathways members can engage. The framework is the Hallmarks of Ageing, first proposed in 2013 and expanded to twelve hallmarks in a 2023 Cell review titled ‘An Expanding Universe’ — a title that tells you something about how the authors see the field.
The Hallmarks framework organises ageing into distinct biological processes, each meeting three criteria: they appear with age, they can be experimentally accelerated, and — crucially — they can be decelerated, halted, or reversed by targeted interventions. The three new hallmarks added in 2023 — disabled autophagy, chronic inflammation, and dysbiosis — map directly onto pillars already in the Forever Well programme, which is how the longevity framework and the daily-life pillars connect.
It is worth being clear upfront that this is not a closed list. The 2013 paper identified nine hallmarks; the 2023 update added three more. The next major review, whenever it comes, will almost certainly add further processes the current research is only beginning to map. Members reading this pillar are encountering a framework that is still under active construction — one where the core concepts are well-established but the edges keep moving. The six pathways the rest of this section focuses on are the ones where the evidence is most mature and the interventions most accessible today. They are not the whole story, and they will not be the whole story a decade from now either.
This pillar focuses on six pathways that carry the most weight for member outcomes. They are not the only hallmarks, but they are the ones where the evidence is most mature, the interventions most accessible, and the connections to the other Forever Well pillars most direct.
The mTOR pathway is the closest thing ageing biology has to a master regulator. It senses the availability of nutrients — particularly protein and amino acids — and tells cells whether to grow or to clean and repair. High nutrient availability keeps mTOR active, which drives growth but suppresses cellular maintenance. Low nutrient availability — caloric restriction, fasting, protein moderation — dampens mTOR, which shifts cells into repair mode. Sustained elevated mTOR signalling is one of the clearest drivers of accelerated ageing in every organism studied, from yeast to mammals.
The most striking demonstration is rapamycin, a drug that inhibits mTOR. In the NIA Interventions Testing Program, rapamycin extended median lifespan in genetically heterogeneous mice even when started late in life — at 600 days, the mouse equivalent of around 60 human years. This was the first unambiguous demonstration that a drug can extend mammalian lifespan when started well past midlife. Caloric restriction in rhesus monkeys — the closest animal model to humans — has similarly shown improvements in healthspan and survival in long-term studies.
For members, the mTOR pathway is engaged by several interventions the Forever Well framework already recommends: Mediterranean-pattern eating with moderate protein, regular periods of time-restricted eating, regular exercise (which temporarily raises mTOR in muscle for growth but lowers it systemically), and avoiding the chronically-elevated insulin signalling that drives metabolic disease. Forever Well does not recommend chronic calorie restriction — the evidence in humans is less clear, the quality-of-life cost is substantial, and the same mechanistic benefits appear reachable through intermittent approaches. This is where the Nutrition, Exercise, and Hormesis pillars all meet the longevity pathway framework.
Sirtuins are a family of enzymes — seven of them in humans — that regulate DNA repair, mitochondrial function, metabolic signalling, and stress responses. They run on NAD+, a coenzyme found in every cell. The problem is that NAD+ levels decline substantially with age. By 60, most people have roughly half the NAD+ they had at 30. As NAD+ drops, sirtuin activity drops with it, and the repair systems that depend on it become less effective.
This is the biology behind the NAD+ precursor supplements — NMN and NR — that have become one of the most active areas in longevity science. Human trials have shown that oral NMN supplementation raises blood NAD+ levels reliably, with early signals of benefit on muscle function, insulin sensitivity, and vascular health. The Supplements pillar covers the compound-level evidence in detail. What matters here is the pathway logic: raising NAD+ gives the sirtuin system the fuel it needs to keep doing its job. TMG (trimethylglycine), also included in Forever Well’s Daily Longevity Core, supports the methylation cycle that keeps NAD+ metabolism running cleanly.
Resveratrol — included in Forever Well’s Daily Longevity Elite at the Gold tier — is the compound most famously linked to sirtuin activation. The picture here is more complicated than early marketing suggested: some sirtuin effects originally attributed to resveratrol have been re-examined, and the cleanest lifespan extension evidence comes from other interventions. But resveratrol remains a reasonable addition to a comprehensive stack, alongside the more strongly-supported NMN and TMG. The Supplements pillar goes into the detailed evidence and the genuine controversy.
As cells age or get damaged, they can enter a state called senescence — a kind of biological retirement where they stop dividing but don’t die. In moderation this is useful: senescent cells prevent damaged DNA from being passed on and help with wound healing. The problem is that they accumulate with age, and they leak out a mix of inflammatory signals called the senescence-associated secretory phenotype, or SASP. That inflammatory output damages neighbouring healthy cells and contributes to the chronic low-grade inflammation that drives most age-related diseases.
The proof that senescent cells are actively driving ageing — not just sitting there — came from a landmark 2011 paper in Nature. A team at the Mayo Clinic engineered mice in which senescent cells could be selectively eliminated. When they were cleared, the mice lived healthier lives with reduced age-related dysfunction. A follow-up study in 2016 in normally-ageing wild-type mice showed that selective clearance of senescent cells extended median lifespan.
This launched the field of senolytics — compounds that selectively kill senescent cells. Some are pharmaceuticals; others are natural compounds. A 2018 Nature Medicine study from the same Mayo Clinic group showed that a dasatinib-plus-quercetin combination eliminated senescent cells and extended lifespan in aged mice — and, importantly, eliminated human senescent cells in tissue samples. Quercetin — one of the two active compounds in that combination — is included in Forever Well’s Daily Longevity Core. Fisetin, also in the Core, is another well-studied natural senolytic. The Supplements pillar covers the dose-level evidence; here what matters is that senescence clearance is no longer hypothetical, and the tools are within reach of a well-designed daily supplement stack.
Autophagy is how cells recycle their own damaged parts — old organelles, misfolded proteins, malfunctioning components. It is one of the most important quality-control systems the body has, and it declines with age. The 2023 Hallmarks update promoted disabled autophagy to its own hallmark category, reflecting how central it has become to ageing biology.
What’s encouraging is that autophagy is highly responsive to intervention. Fasting induces it — this is one of the cleanest biological reasons why time-restricted eating and periodic longer fasts appear beneficial. Exercise induces it. Caloric restriction induces it. And one particular supplement compound, spermidine, appears to induce autophagy at physiologically meaningful doses. A 2018 Science review from the Madeo group covers the evidence: dietary spermidine intake correlates with lower all-cause mortality in large German cohorts, and animal studies show lifespan extension through autophagy induction. Spermidine is included in Forever Well’s Daily Longevity Elite at the Gold tier.
For members, autophagy is one of the strongest arguments for the Forever Well approach — because it responds to so many of the pillars simultaneously. A member who fasts overnight, exercises regularly, eats Mediterranean-pattern, and takes a well-designed supplement stack is engaging the autophagy pathway through four independent routes. The effects stack.
Mitochondria are the energy-producing organelles in every cell, and they age. mtDNA accumulates damage, the production of new mitochondria slows, and the removal of damaged mitochondria — a process called mitophagy — becomes less efficient. The result is declining cellular energy, rising oxidative damage, and a contribution to many of the functional symptoms of ageing.
The good news is that mitochondria respond powerfully to exercise — particularly zone 2 aerobic training, which builds mitochondrial density in working muscle. This is one of the key biological reasons the Exercise pillar emphasises it. On the supplement side, urolithin A, a compound produced when gut bacteria metabolise pomegranate-derived precursors, has emerged as the most targeted mitophagy inducer available. A 2019 Nature Metabolism trial from Amazentis showed urolithin A is safe in humans, reaches bioavailable levels, and improves molecular markers of mitochondrial health. Urolithin A is included in Forever Well’s Daily Longevity Elite. CoQ10 in its ubiquinol form, also in the Elite stack, supports the electron transport chain that mitochondria use to generate energy — particularly relevant as endogenous production of CoQ10 falls with age. The Supplements pillar covers both compounds in detail.
Telomeres are the protective caps at the end of chromosomes. They shorten slightly every time a cell divides, and when they get critically short, the cell can no longer divide safely — it either dies or becomes senescent. Telomere attrition is one of the classical hallmarks of ageing. Lifestyle factors that influence telomere length include exercise, diet, meditation, and chronic stress, with strong evidence particularly from the work of Elizabeth Blackburn (Nobel laureate for telomere biology) and Elissa Epel. The Meditation pillar covers the stress-telomere angle in detail; here what matters is that telomere measurement is part of Forever Well’s Gold-tier biological age testing.
The epigenome — the chemical tags that sit on top of DNA and control which genes are switched on or off — also changes with age. These changes are not random: they follow patterns consistent enough that they can be used to estimate biological age directly. This is the basis of the DNA methylation clocks that have transformed ageing research over the last decade.
No pillar on longevity pathways written today would be complete without discussing GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the next-generation dual and triple agonists now in late-stage trials. These drugs were developed for type 2 diabetes and obesity, but what the clinical evidence is now showing is considerably broader. Major cardiovascular outcomes trials have documented substantial reductions in heart attacks, strokes, and cardiovascular deaths. Kidney function preserved. Liver disease — specifically metabolic dysfunction-associated steatohepatitis, previously almost untreatable — resolved in around 63% of patients in the ESSENCE phase 3 trial. Early signals suggest reduced risk of Alzheimer’s disease, with two major phase 3 trials (evoke and evoke+) now reporting. Epidemiological data is hinting at lower incidence of several obesity-related cancers.
The striking finding, from the SELECT cardiovascular outcomes trial, is that roughly a third of the cardiovascular benefit of semaglutide is independent of weight loss. Something more fundamental is going on. GLP-1 receptors turn out to be distributed across virtually every organ system, and activation of them produces effects that look remarkably like reaching several ageing pathways at once — reduced chronic inflammation, improved mitochondrial function, better metabolic flexibility, reduced oxidative stress, improved vascular health. At the 2024 Aging Research and Drug Discovery meeting in Copenhagen, scientists from Novo Nordisk and Eli Lilly proposed that GLP-1 agonists may be the first true longevity drugs — a claim that would have seemed premature even five years ago.
The honest position is that the mechanisms are still being mapped. Members taking these drugs today for diabetes or weight loss are benefiting from a pharmacological intervention that reaches pathways we do not yet fully understand — and that appears to deliver benefit across more of the biology of ageing than any previous class of drugs. This is rare in medicine. It is also a useful reminder that the longevity pathway map is not complete, and that sometimes an intervention works through mechanisms we only identify in retrospect.
Forever Well’s position on GLP-1s is straightforward. They are prescription medications, not supplements, and are prescribed through appropriate clinical channels for members who meet the clinical criteria. Forever Well does not prescribe them directly. But for members who are on them — or who are considering them with their GP or specialist — they fit extremely well with the longevity pathway framework this pillar describes. The Forever Well team at Gold tier can help members interpret their blood markers and biological age trends in context of GLP-1 treatment, and integrate the drug effect with the lifestyle and supplementation work the rest of the programme is doing. Over the next five years, as these drugs become cheaper, oral formulations arrive, and evidence broadens further, they are likely to become a larger part of the conversation for more members.
Biological age testing has moved through three generations. The first-generation clock, developed by Steve Horvath in 2013, uses 353 specific sites on the DNA where methylation levels correlate with chronological age. It was a breakthrough — the first accurate, tissue-general measure of biological age from a simple blood or saliva sample.
The second generation improved on this by training the clocks on clinical outcomes rather than on chronological age directly. Levine’s PhenoAge, published in 2018, uses 513 CpG sites and is substantially better at predicting mortality, healthspan, and physical function. Importantly for members, PhenoAge is influenced by measurable lifestyle factors: exercise, fruit and vegetable intake, and HDL cholesterol are associated with slower epigenetic ageing; smoking, elevated inflammation, and metabolic dysfunction are associated with faster.
The third generation, represented by DunedinPACE (2022), takes a different approach again. It is derived from a single-year birth cohort — the Dunedin Study, which has followed people born in 1972 and 1973 for their entire lives — and trained on how fast each person’s multi-organ function declined over twenty years. DunedinPACE measures the pace at which someone is ageing right now, and is specifically designed to be sensitive to intervention-driven change. It is the clock most useful for tracking whether sustained lifestyle and programme changes are actually slowing someone’s ageing.
Forever Well’s Gold-tier biological age testing uses current-generation DNA methylation clocks alongside telomere length measurement and the full advanced blood biomarker panel. The value is not in a single snapshot — it is in the trend over months and years, which is what third-generation clocks like DunedinPACE are built to detect.
The last thing worth being clear about is where the evidence sits at each tier. Mechanism evidence — what the pathways are, how they interact, how interventions reach them — is now settled science. Animal evidence for intervention effects on lifespan and healthspan is extensive and well-replicated. Human intervention evidence is the frontier, and it is maturing rapidly. Early biological-age-reversal pilots like the TRIIM study sit alongside the rapidly-developing GLP-1 evidence base to suggest that human longevity interventions are moving from hypothetical to practical faster than most researchers expected a decade ago. Forever Well’s programme sits firmly in the lifestyle and supplementation band, built on the strongest available evidence without overclaiming what the frontier research has yet to prove. The biology is real, the interventions work, and the evidence base is growing every year. The 2014 Cell commentary that formally launched the field of geroscience — linking ageing biology to chronic disease prevention — is now ten years old, and the research output has increased roughly tenfold since. For members, this means they are engaging with science that is maturing from promising into established, and will continue to do so over the years they spend on the programme.
Six pathways, plus a rapidly-opening frontier. Each measurable. Each modifiable. Each connected to daily habits, targeted supplementation, and — increasingly — new classes of medication in ways the evidence now firmly supports.
